Factor V Leiden Mutation Increases the Risk for Venous Thromboembolism in Cancer Patients - Results from the Vienna Cancer and Thrombosis Study (CATS).
J Thromb Haemost. 2014 Nov 10;
Authors: Pabinger I, Ay C, Dunkler D, Thaler J, Reitter EM, Marosi C, Zielinski C, Mannhalter C
BACKGROUND: Patients with cancer are at an increased risk for venous thromboembolism (VTE). The risk varies markedly in different patient populations. Factor V Leiden (FV-Leiden) is the most common genetic risk factor for VTE and the impact of FV Leiden on cancer-associated thrombosis is not yet fully elucidated.
OBJECTIVE: To study the impact of FV-Leiden on the risk of thrombosis in cancer patients.
METHODS: In the prospective observational Vienna Cancer and Thrombosis Study 982 patients were included and were followed until occurrence of VTE or death, for a maximum period of 2 years. FV-Leiden was determined by genotyping at inclusion. Main outcome measures were symptomatic or lethal objectively confirmed VTE.
RESULTS: Of the 982 patients FV-Leiden was diagnosed in 72 (7.3%, 70 were heterozygous, 2 homozygous). Ten of 72 (13.9%) patients with FV-Leiden developed VTE, whereas this was the case in 69 of 910 (7.6%) patients without FV-Leiden. In multivariate analysis that included age, sex, different tumour types, tumour stage, newly diagnosed versus recurrence of disease and the treatment modalities the hazard ratio (HR) was 2.0 [95% confidence interval (CI) 1.0-4.0]. In Kaplan Meier analysis the probability for development of VTE was 13% in those with and 5.7% in those without FV-Leiden after 6 months; after one year the corresponding risks were 15% and.7.3% CONCLUSIONS: FV-Leiden is a genetically determined and thus disease-independent parameter, which is associated with VTE in cancer patients and could therefore be used for individual risk assignment. This article is protected by copyright. All rights reserved.
PMID: 25381723 [PubMed - as supplied by publisher]